Record earnings, margin durability in question amid capex ramp

Delivered ₹345.0 Cr, confirmed YoY growth +207.4%

Delivered ₹2,577.6 Cr; call slightly overstated by ₹14.4 Cr. Actual YoY 36.4%, not 35%

Implies PAT+D+Tax+Interest ≈ ₹500-550 range; OPM 21% confirmed. No EBITDA breakdown given but plausible

Clarified as 'run rate basis' only, April weak due to shutdown + propylene shortage. Not a sustained quarterly volume

Management later stated: 'I don't think there was any place where we were able to get any benefit' from inventory

No longer 'nitration company that buys nitric acid'; now 'nitrogen company that nitrates.' Strategic shift unlocks downstream chemistry (diazotization, fluorination). Announced on call; tangible moat.

From ~3.5L tonne 'maturity' to 4L tonne target via advanced process controls + ₹70-100 Cr further invest. Prior call vague; now concrete roadmap. MIBC capacity exceeded design spec in pre-comm runs.

₹11.5 Cr propylene/polycarbonate project debt tied up at 'competitive rates.' 60:40 debt:equity; peak debt ₹8-8.5 Cr, D/E <1x. Financial flexibility confirmed.

Flow chemistry benefits 'next FY, not this FY.' Fluorination, amination still in customer validation (months to 12+ months cycles). Margin upside deferred.

Q1 operated under duty-free imports; Q2+ duty back on phenol. Government recognition of domestic supply adequacy. Supports pricing but also signals macro demand volatility.

Run rate basis only in Q1; April weak (shutdown + propylene shortage). 'Significant periods' at run rate, but not constant. Aiming for 4L tonne target via debottlenecking, reducing summer-winter delta.

Declined to comment on spreads; highlighted operational excellence on RM sourcing vs public indices. Stated achieved prices 'better than reflected on international index.'

Product quality approved, best-in-class. Pre-comm runs met target RM & utility norms. Confident of 100%+ ramp very quickly. Common OSBLs will uplift site profitability.

Refrained from quantifying. Stated margins 'inline or better than average margin profile of AI.' Integrated asset fungibility provides upside.

Phenol aligned with PDH propylene supply. Polycarbonate disengaged; targeting H2 FY28-29 (clarified FY28-29, not FY28). BPA couple months after. Balancing pace vs not losing market share.

April saw higher RM prices vs Q4; engaged suppliers on margin parity. As availability improved, securing competitively. Propylene from PDH will improve further.

High freight/insurance rates. Agile approach: e.g., changed sodium nitrite formulation (added water) to reduce hazmat class, lowering shipping cost. Engaging on CIF-to-FOB, consolidation strategies.

Red ocean competition in existing chemistries (nitration, etc.); new molecules faced margin pressure from low-cost competitors. China now tightening; competition intensity improving. New molecules at better margins; entering new applications with higher purity. Results in next few years.

Flow chemistry platform in NOx chemistry; batch reaction 16-18 hours now 45-52 seconds. Reduces hazardous intermediate inventory, rapid changeover. Coming next FY, not current FY. Market traction via seed samples.

Spent ₹1.2 Cr so far. FY27 further ₹1-1.5 Cr. Total FY27 spend ~₹3.2 Cr (site dev, construction, long-lead items). Peak debt ₹8-8.5 Cr; D/E <1x.

Declined to comment on integrated margin. Stated has 'formidable IRR' and banks convinced. No specifics.

Declined to comment; under NDA.

Run-rate basis only. April spotty (maintenance shutdown preponed). Parts of quarter on stockpiled intermediates, part on bought-out propylene/benzene.

First time hearing of 1.6 ratio. Cannot align with specific number. Process is condensation + reduction; implemented divided-wall columns for efficiency. World-scale cost position.

Prior call: 'continued positive performance.' This call hints 'improving demand, visibility' but no number.

Based on MIBK/MIBC ramp, flow chemistry, new asset launches. But management refused to quantify margin profiles.

Debt funding closed. ₹1.2 Cr spent Q1; ₹1-1.5 Cr more in FY27. Funded via 60:40 debt:equity ratio.

Phenolics relies on propylene, benzene sourcing. April saw shortage + higher prices. Management agile but margins eroded if RM pricing power lost.

1L tonne/quarter phenol run-rate hit on 'run rate basis' only; April weak due to maintenance shutdown + propylene scarcity. Quarterly volumes may not sustain.

₹11.5 Cr polycarbonate/propylene capex targeting H2 FY28-29. MIBK/MIBC & acetophenone commissioning by Q2 but pre-comm runs only. Cost/schedule slippage risk high.

Flow chemistry, fluorination, amination projects still in R&D/customer validation. Margin uplift deferred to 'next FY, not this FY.' Customer cycles 12-24+ months.

MIBK/MIBC margin profile not quantified; only 'inline or better than average AI.' Phenolics EBIT margin 23.5% driven by RM arbitrage and demand strength—both volatile.

Call explicitly flags geopolitical developments, pricing volatility. Freight, insurance rates escalating. War premium in Middle East (export market). Macro uncertainty on demand visibility.